Targeted superantigens for immunotherapy of haematopoietic tumours

Vox Sanguinis

Volumn 74, Issue SUPPL. 2, 1998, Pages 483-487

  Tötterman, Thomas H ^a   Gidlof C ^a   Ragnarsson, L ^a   Hogbom E ^a   Lindeberg, M ^a   Von der Lehr, N ^a   Einarsson, A ^a   Soegaard M ^b   Kristensson, K ^b   Kalland, T ^b   Dohlsten, M ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b Pharmacia & Upjohn AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DR ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

EID: 0031821853     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1423-0410.1998.tb05461.x     Document Type: Conference Paper

References (36)

1. Aisenberg AC: Coherent view of non-Hodgkin's lymphoma. J Clin Oncol 1995; 13:2656-2675.
2. Dillman RO: Antibodies as cytotoxic therapy. J Clin Oncol 1994; 12:1497-1515.
3. Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles T-M, Dallaire BK, Wey K, Roystone I, Davis T, Levy R: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90:2188-2195.
4. Sausville EA, Headlee D, Stetler-Stevenson M, et al.: Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study, Blood 1995; 85:3457-3465.
5. Grossbard ML, Gribben JG, Freedman AS, Lambert JM, Kinsella J, Rabinowe SN, Eliseo L, Taylor JA, Blättler WA, Epstein CL, Nadler LM: Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood 1993; 81:2263-2271.
6. Uckun FM, Evans WE, Forsyth CJ, Waddick KG, T.-Ahlgren L, Chelstrom LM, Burkhardt A, Bolen J, Myers DE: Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science 1995; 267:886-891.
7. Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, Fisher DR, Porter B, Matthews DC, Gooley T, Bernstein ID: Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995; 346:336-340.
8. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA, Butchko GM, Glenn SD, Wahl RL: Radioimmunotherapy of B-cell lymphoma with [131I]anti-Bl (anti-CD20) antibody. N Engl J Med 1993; 329:459-465.
9. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992; 327:1209-1215.
10. Tao M-H, Levy R: Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccin for B-cell lymphoma. Nature 1993; 362:755-758.
11. Hsu FJ, Benike C, Fagnoni F, Lues TM, Czerwinski D, Taidi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphuma using autologous antigen-pulsed dendritic cells. Nature Med 1996; 2:52-58.
12. Bataille R, Barlogie B, Lu ZY, Rossi J-F, Lavabre-Bertrand T, Beck T, Wijdenes J, Brochier J, Klein B: Biologie effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995; 86:685.
13. Stasi R, Venditti A, Del Poeta G, Aronica G, Abruzzese E, Pisani F, Cecconi M, Masi M, Amadori S: High-dose chemotherapy in adult acute myeloid leukemia: rationale and results. Leukemia Res 1996; 20:535-549.
14. Martinez-Climent JA, Lane NJ, Rubin CM, Morgan E, Johnstone HS, Mick R, Murphy SB, Vardiman JW, Larson RA, Le Beau MM, Rowley JD: Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo. Leukemia 1995; 9:95-101.
15. Cortes JE, Talpaz M, Kantarjian H: Chronic myelogenous leukemia: a review. Am J Med 1996; 100:555-570.
16. Roy DC, Griffin JD, Belvin M, Blättler WA, Lambert JM, Ritz J: Anti-MY9-blocked-ricin: An immunotoxin for selective targeting of acute myeloid leukemia cells, Blood 1991; 77:2404-2412.
17. Jurcic JG, Caron PC, Miller Jr WH, Yao TJ, Maslak P, Finn RD, Larson SM, Warrell Jr RP, Scheinberg DA: Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans Retinoic acid and anti-CD33 monoclonal antibody M195. Leukemia 1995; 9:244-248.
18. Schwanz MA, Lovett DR, Redner A, Finn RD, Graham MC, Divgi CR, Dantis L, Gee TS, Andreeff M, Old LJ, Larson SM, Scheinberg DA: Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol 1993; 11:294-303.
19. Scheinberg DA, Lovett D, Divgi CR, Graham MC, Berman E, Pentlow K, Feirt N, Finn RD, Gee TS, Larson SM, Oettgen HF, Old LJ: A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and intemalization of radionuclide, J Clin Oncol 1991; 9:478-490.
20. Gottlieb DJ, Brenner MK, Heslop HE, et al: A Phase I trial of recombinant interleukin-2 following high dose chemoradiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease. Br J Cancer 1989; 60:610-615.
21. Gottlieb DJ, Prentice HG, Heslop HE, et al: Effects of recombinant interleukin-2 administration on cytotoxic effector function following intensive chemoradiotherapy. Blood 1989; 74:2335-2342.
22. Rosenberg SA, Lotze MT, Mule JJ: New approaches to the immunotherapy of cancer using interleukin-2. Ann Intern Med 1988; 108:853-864.
23. Biaise D, Olive D, Stoppa AM, et al: Hematologic and immunologic effects of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1990; 76:1092-1097.
24. Abrahmsen L, Dohlsten M, Segrén S, Björk P, Jonsson E, Kalland T: Characterization of two distinct MHC class II binding sites in the superantigen staphylococcal enterotoxin A. EMBO J 1995; 14:2978-2986.
25. Marrack P, Kappler J: The Staphylococcal enterotoxins and their relatives. Science 1990; 248:705-711.
26. Herman A, Labrecque N, Thiobodeau J, Marrack P, Kappler JW, Sékaly R-P: Identification of the staphylococcal enterotoxin A superantigen binding site in the β1 domain of the human histocompatibility antigen HLA-DR, Proc Natl Acad Sci (USA) 1991; 88:9954-9958.
27. Dohlsten M, Abrahmse'n L, Björk P, Lando PA, Hedlund G, Forsberg G, Brodin T, Gascoigne NRJ, Förberg C, Lind P, Kalland T: Monoclonal antibody-superantigen fusion proteins: tumor specific agents for T cell based tumor therapy. Proc Natl Acad Sci (USA) 1994; 91:8945-8949.
28. Dohlsten M, Hedlund G, Sjögren H-O, Carlsson R: Two subsets of human CD4+ T helper cells differing in kinetics and capacities to produce interleukin 2 and inteferon-gamma can be defined by the Leu-18 and UCHL1 monoclonal antibodies. Eur J Immunol 1988; 18:1173-1178.
29. Fischer H, Dohlsten M, Andersson U, Hedlund G, Ericsson P-O, Hansson J, Sjögren HO: Production of TNF-α and TNF-β by staphylococcal enterotoxin A activated human T cells. J Immunol 1990; 144:4663-4669.
30. Dohlsten M, Lando PA, Hedlund G, Trowsdale J, Kalland T: Targeting of human cytotoxic T lymphocytes to MHC class II-expressing cells by staphylococcal enterotoxins. Immunology 1990; 71:96-100.
31. Wallgren A-C, Festin R, Gidlöf C, Dohlsten M, Kalland T, Tötterman TH: Efficient killing of chronic B-lymphocytic leukemia cells by superantigen-directed T cells. Blood 1993; 82:1230-1238.
32. Gidlöf C, Dohlsten M, Kalland T, Tötterman TH: Antibodies are capable of directing superantigen-mediated T-cell killing of chronic B lymphocytic leukemia cells. Leukemia 1995; 9:1534-1542.
33. Gidlöf C, Dohlsten M, Lando P, Kalland T, Sundström C, Tötterman TH: A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies. Blood 1997; 89:2089-2097.
34. Wijdenes J, Vooijs WC, Clément C, Post J, Morard F, Vita N, Laurent P, Sun R-X, Klein B, Dore J-M: A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan1. Br J Haematol 1996; 94:318-323.
35. Carbone A, Gloghini A, Gattei V, Degan M, Improta S, Aldinucci D, Canzonieri V, Perin T, Volpe R, Gaidano G, Zagonel V, Pinto A; Reed-Sternberg cells of classical Hodgkin's disease react with the plasma cell-specific monclonal antibody B-B4 and express human syndecan-1. Blood 1997; 89:3787-3794.
36. Gidlöf C, Carlson B, Dohlsten M, Tötterman TH: Antibody-directed superantigen-mediated T cell killing of myeloid leukaemic cell line cells. Eur J Haematol 1998 (in press).